Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of hydroxychloroquine (600mgBID) combined with
gemcitabine (1000mg/m2,d1,8) in the third-line and above treatment of advanced NSCLC.